3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
Fluorouracil
616
Oxaliplatin
579
Gemcitabine
492
Capecitabine
445
Leucovorin
427
Irinotecan
390
Bevacizumab
330
Cisplatin
320
Radiotherapy
245
Cetuximab
215
Sorafenib
167
pembrolizumab
152
Docetaxel
150
Paclitaxel
140
Nivolumab
128
Albumin-Bound Paclitaxel
108
130-nm albumin-bound paclitaxel
108
Folfox protocol
101
Panitumumab
95
Erlotinib Hydrochloride
95
Surgical Procedures, Operative
86
regorafenib
84
S 1 (combination)
81
Drug Therapy
80
Radiation
69
Carboplatin
65
Neoadjuvant Therapy
64
Colonoscopy
64
Radiosurgery
63
Surveys and Questionnaires
60
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
enadenotucirev
×
Gastrointestinal
×
Clear all
NCT03916510
2025-02-06
CEDAR
University of Oxford
Phase 1
Completed
12 enrolled
13 charts
NCT02636036
2021-11-09
SPICE
Akamis Bio
Phase 1
Completed
51 enrolled
NCT02028442
2020-03-12
EVOLVE
Akamis Bio
Phase 1/2
Completed
61 enrolled